MX351863B - Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. - Google Patents

Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.

Info

Publication number
MX351863B
MX351863B MX2014009991A MX2014009991A MX351863B MX 351863 B MX351863 B MX 351863B MX 2014009991 A MX2014009991 A MX 2014009991A MX 2014009991 A MX2014009991 A MX 2014009991A MX 351863 B MX351863 B MX 351863B
Authority
MX
Mexico
Prior art keywords
salt
quinolylpyrrolopyrimidyl
fused
ring compound
inhibition activity
Prior art date
Application number
MX2014009991A
Other languages
English (en)
Other versions
MX2014009991A (es
Inventor
Katsumasa Nonoshita
Takeshi Sagara
Sachie Otsuki
Satoru Ito
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2014009991A publication Critical patent/MX2014009991A/es
Publication of MX351863B publication Critical patent/MX351863B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona un nuevo compuesto que tiene una acción inhibitoria contra EGFR y que tiene efectos inhibitorios del crecimiento celular; la presente invención además proporciona una preparación farmacéutica útil para prevenir y/o tratar el cáncer, basado en el efecto inhibitorio del EGFR del compuesto; un compuesto representado por la siguiente fórmula (I) (ver Fórmula) o una sal del mismo.
MX2014009991A 2012-02-23 2013-02-22 Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. MX351863B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012037565 2012-02-23
PCT/JP2013/054615 WO2013125709A1 (ja) 2012-02-23 2013-02-22 キノリルピロロピリミジル縮合環化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2014009991A MX2014009991A (es) 2014-09-08
MX351863B true MX351863B (es) 2017-10-30

Family

ID=49005885

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009991A MX351863B (es) 2012-02-23 2013-02-22 Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.

Country Status (15)

Country Link
US (1) US8889666B2 (es)
EP (1) EP2722332B1 (es)
JP (1) JP5557963B2 (es)
KR (1) KR101660145B1 (es)
CN (1) CN104136438B (es)
CA (1) CA2861980C (es)
DK (1) DK2722332T3 (es)
ES (1) ES2580530T3 (es)
HU (1) HUE029343T2 (es)
MX (1) MX351863B (es)
PL (1) PL2722332T3 (es)
RU (1) RU2581039C1 (es)
SG (1) SG11201402876UA (es)
TW (1) TWI496783B (es)
WO (1) WO2013125709A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014129596A1 (ja) * 2013-02-22 2014-08-28 大鵬薬品工業株式会社 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物
EP3037424B1 (en) * 2013-08-22 2017-11-08 Taiho Pharmaceutical Co., Ltd. Novel quinoline-substituted compound
DK3279202T3 (da) * 2015-03-31 2020-08-17 Taiho Pharmaceutical Co Ltd Krystal af 3,5-disubstitueret benzenalkynylforbindelse
WO2017064558A1 (ja) * 2015-10-14 2017-04-20 大鵬薬品工業株式会社 新規免疫賦活化剤
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
JP7065103B2 (ja) 2017-09-01 2022-05-11 大鵬薬品工業株式会社 エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤
CN112574208B (zh) * 2019-09-29 2022-09-13 深圳市塔吉瑞生物医药有限公司 取代的稠合三环衍生物及其组合物及用途
WO2022121967A1 (zh) * 2020-12-09 2022-06-16 南京药石科技股份有限公司 Egfr酪氨酸激酶抑制剂及其用途
US12037346B2 (en) 2021-04-13 2024-07-16 Nuvalent, Inc. Amino-substituted heteroaryls for treating cancers with EGFR mutations
CN115785107B (zh) * 2022-12-15 2024-11-12 南京雷正医药科技有限公司 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007138264A (ru) 2005-03-17 2009-09-10 Новартис АГ (CH) N-[3-(1-АМИНО-5,6,7,8-ТЕТРАГИДРО-2,4,4b-ТРИАЗАФЛУОРЕН-9-ИЛ)ФЕНИЛ]БЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИН/ТРЕОНИНКИНАЗ, ПРЕЖДЕ ВСЕГО КИНАЗ В-RAF
WO2007075554A2 (en) * 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
EP2051982A1 (en) * 2006-08-10 2009-04-29 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted sulfur containing heterobicyclic protein kinase inhibitors
EA018573B1 (ru) * 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
SG10201508035TA (en) * 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
CN102146059A (zh) * 2010-02-08 2011-08-10 上海艾力斯医药科技有限公司 喹唑啉衍生物、制备方法及其应用
MX342164B (es) * 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
NZ710636A (en) * 2010-11-01 2017-02-24 Celgene Avilomics Res Inc Heterocyclic compounds and uses thereof

Also Published As

Publication number Publication date
HUE029343T2 (en) 2017-02-28
KR20140117647A (ko) 2014-10-07
SG11201402876UA (en) 2014-12-30
ES2580530T3 (es) 2016-08-24
CN104136438A (zh) 2014-11-05
EP2722332A4 (en) 2014-04-23
RU2581039C1 (ru) 2016-04-10
CN104136438B (zh) 2016-04-06
DK2722332T3 (en) 2016-06-20
WO2013125709A1 (ja) 2013-08-29
CA2861980A1 (en) 2013-08-29
JP5557963B2 (ja) 2014-07-23
CA2861980C (en) 2016-11-08
KR101660145B1 (ko) 2016-09-26
TWI496783B (zh) 2015-08-21
US8889666B2 (en) 2014-11-18
PL2722332T3 (pl) 2016-10-31
US20140057899A1 (en) 2014-02-27
AU2013223052A1 (en) 2014-07-03
HK1202862A1 (zh) 2015-10-09
EP2722332B1 (en) 2016-04-20
TW201339160A (zh) 2013-10-01
EP2722332A1 (en) 2014-04-23
MX2014009991A (es) 2014-09-08
JPWO2013125709A1 (ja) 2015-07-30

Similar Documents

Publication Publication Date Title
MX351863B (es) Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo.
PH12016500225A1 (en) Novel quinoline-substituted compound
PH12017502141A1 (en) Compounds and their methods of use
PH12015501058A1 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
TN2012000401A1 (en) Heterocyclic compound
MX2013011329A (es) Combinaciones de compuestos inhibidores de akt y erlotinib y metodos de uso.
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
IN2015DN00827A (es)
PH12012502128B1 (en) Chemical compounds
AU2012324803A8 (en) (hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
GEP201706725B (en) Compounds and compositions as inhibitors of mek
PH12015501038A1 (en) Inhibitors of iap
GEP201706687B (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
MX2014002832A (es) Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
MY160902A (en) Process for the preparation of the L-arginine salt of perindopril
PH12013501018A1 (en) 177lutetium-labeled bombesin analogs for radiotherapy
NZ709094A (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer

Legal Events

Date Code Title Description
FG Grant or registration